Alfred  Altomari net worth and biography

Alfred Altomari Biography and Net Worth

Mr. Altomari has served as our Chairman of the board and Chief Executive Officer since October 2016 and has been a member of our board of directors since February 2004. Mr. Altomari served as President and Chief Executive Officer from 2010 to 2016. Previously Mr. Altomari served as Agile's Executive Chairman from 2004 to 2010. From 2003 to 2008, Mr. Altomari held multiple senior management positions at Barrier Therapeutics, Inc., including Chief Commercial Officer, Chief Operating Officer, and Chief Executive Officer. In 2008, in his role as Chief Executive Officer and as a member of Barrier's board of directors, Mr. Altomari completed the successful sale of Barrier to Stiefel Laboratories, which was subsequently acquired by GlaxoSmithKline plc. From 1982 to 2003, Mr. Altomari held numerous executive roles in general management, commercial operations, business development, product launch preparation, and finance with Johnson & Johnson. Mr. Altomari also serves on the board of directors of Insmed Inc. and Baudax Bio, Inc. He previously served on the board of directors of Recro Pharm, Inc. Mr. Altomari received an M.B.A. from Rider University and his B.S. from Drexel University. He currently serves on the LeBow College of Business Advisory Board and the Board of the Charles D. Close School of Entrepreneurship at Drexel University. He currently is a member of the Board of Directors for TASK (Trenton Area Soup Kitchen).

What is Alfred Altomari's net worth?

The estimated net worth of Alfred Altomari is at least $97,157.93 as of August 26th, 2022. Mr. Altomari owns 64,343 shares of Agile Therapeutics stock worth more than $97,158 as of November 26th. This net worth estimate does not reflect any other assets that Mr. Altomari may own. Additionally, Mr. Altomari receives a salary of $646,530.00 as CEO at Agile Therapeutics. Learn More about Alfred Altomari's net worth.

How old is Alfred Altomari?

Mr. Altomari is currently 65 years old. There are 5 older executives and no younger executives at Agile Therapeutics. Learn More on Alfred Altomari's age.

What is Alfred Altomari's salary?

As the CEO of Agile Therapeutics, Inc., Mr. Altomari earns $646,530.00 per year. Learn More on Alfred Altomari's salary.

How do I contact Alfred Altomari?

The corporate mailing address for Mr. Altomari and other Agile Therapeutics executives is 101 POOR FARM ROAD, PRINCETON NJ, 08540. Agile Therapeutics can also be reached via phone at (609) 683-1880 and via email at [email protected]. Learn More on Alfred Altomari's contact information.

Has Alfred Altomari been buying or selling shares of Agile Therapeutics?

Alfred Altomari has not been actively trading shares of Agile Therapeutics during the last ninety days. Most recently, on Friday, August 26th, Alfred Altomari bought 50,000 shares of Agile Therapeutics stock. The stock was acquired at an average cost of $0.45 per share, with a total value of $22,500.00. Following the completion of the transaction, the chief executive officer now directly owns 64,343 shares of the company's stock, valued at $28,954.35. Learn More on Alfred Altomari's trading history.

Who are Agile Therapeutics' active insiders?

Agile Therapeutics' insider roster includes Alfred Altomari (CEO), Jason Butch (Insider), and Dennis Reilly (CFO). Learn More on Agile Therapeutics' active insiders.

Alfred Altomari Insider Trading History at Agile Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/26/2022Buy50,000$0.45$22,500.0064,343View SEC Filing Icon  
7/29/2021Buy26,200$1.26$33,012.00View SEC Filing Icon  
5/18/2021Buy20,000$1.61$32,200.00488,710View SEC Filing Icon  
3/23/2021Buy12,500$2.00$25,000.00468,710View SEC Filing Icon  
2/27/2020Buy10,000$2.71$27,100.00301,611View SEC Filing Icon  
6/10/2019Buy20,000$1.27$25,400.00258,568View SEC Filing Icon  
3/25/2019Buy25,000$1.54$38,500.00238,568View SEC Filing Icon  
8/25/2017Buy10,000$3.34$33,400.00161,587View SEC Filing Icon  
5/11/2017Buy10,000$3.51$35,100.00151,587View SEC Filing Icon  
6/2/2015Buy2,500$8.73$21,825.00View SEC Filing Icon  
See Full Table

Alfred Altomari Buying and Selling Activity at Agile Therapeutics

This chart shows Alfred Altomari's buying and selling at Agile Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Agile Therapeutics Company Overview

Agile Therapeutics logo
Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $1.51
Low: $1.51
High: $1.52

50 Day Range

MA: $1.49
Low: $1.43
High: $1.51

2 Week Range

Now: $1.51
Low: $0.20
High: $2.63

Volume

120,900 shs

Average Volume

352,864 shs

Market Capitalization

$10.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58